Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
COLUMN
Loss Aversion: Why Candidates Reject Offers
Philip Carrigan Every day, recruiters around Asia speak to candidates to pitch positions and close deals; and sometimes offers are rejected. No matter what the market, one thing that is consistent is that the best candidates, the ones the client…
To read the full story
COLUMN
- AI in HR: Navigating the Ethical Minefield
November 28, 2025
- The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
- The Keen Eye: Awareness as a Leadership Cornerstone
September 29, 2025
- A “50-Billion-Yen Plus” Newcomer
September 4, 2025
- AI in Japanese Pharma: Now, Not Later!
August 29, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…